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Abstract  
Background: Differential treatment between trial arms has been suggested to bias prostate cancer (PC) 
mortality in the European Randomized Study of Screening for Prostate Cancer (ERSPC). 
Objective: To assess the contribution of treatment differences on the observed PC mortality reduction 
between the screening (SA) and control arm (CA). 
Design, Setting and Participants: 14,136 men with PC (SA: 7,310; CA: 6,826) in the core age group (55-
69 years) at 16 years of follow-up.  
Outcome Measurements: Observed versus estimated number of PC deaths by treatment allocation in 
the SA and CA, respectively. 
Statistical Analysis:  Primary treatment allocation was modelled using multinomial logistic regression 
adjusting for: center, age, year, prostate-specific antigen, Grade Group, and TNM stage. For each 
treatment, logistic regression models were fitted for risk of PC death, separately for the SA and CA, and 
using the same covariates as for the treatment allocation model. Treatment probabilities were 
multiplied with estimated PC death risks for each treatment based on one arm, then summed and then 
compared to the observed number of deaths.  
Results: When comparing the estimated differences (after controlling for clinical and pathological 
variables) with the observed treatment distributions between the ERSPC trial arms, the residual 
discrepancies weremarginal: hormonal therapy [0.1% vs. 9.4%], radical prostatectomy [0.8% vs. 10.1%], 
radiotherapy [3.3% vs. 7.9%], and surveillance [2.6% vs. 7.2%].  
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We estimated a reduction in the between-group risk of PC mortality to be 0.01% [95% CI -0.3%, 0.2%] 
when applying the SA model to the CA and 0.05% (95% CI (-0.1%, 0.2%) when applying the CA model SA, 
had the two groups received identical primary treatment given clinical characteristics. Because the 
observed difference between groups was 4.2%, our findings suggest that differential treatment explains 
only a trivial proportion of the main findings of the ERSPC trial.  
Limitation: Only data on primary treatment was available.  
Conclusion: Use of PSA remains the predominant explanation for the reduction in PC mortality seen in 
the ERSPC trial and is not attributable to differential treatment between trial arms.  
Patient Summary: This study shows that the prostate cancer deaths in the European screening trial 
(ERSPC) were prevented because men were diagnosed and treated earlier through PSA-screening and 
not because of different, or better, treatment in the screening arm compared to the control arm. 
Take Home Message: The reduction in prostate cancer mortality in the European Randomized Study of 
Screening for Prostate Cancer (ERSPC) is a result of early detection and not differential treatment 
between trial arms. 
Twitter Summary: Prostate cancer mortality reduction in ERSPC trial due to early detection and not 
differential treatment 
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Introduction 
The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown that prostate-
specific antigen (PSA) can reduce prostate cancer (PC) mortality by 21% at 13 years.(1)  It has been 
questioned whether this reduction is an effect of screening and early detection, or whether differential 
treatments between trial arms could have resulted in superior outcomes in the screening arm (SA) vs. 
control arm (CA) of the trial(2, 3). Others have hypothesized that the net reduction in prostate cancer 
deaths in ERSPC was not a result of earlier detection of more curable cancers in the SA through PSA-
screening, but rather a result of more prostate cancer deaths in the CA where “androgen deprivation 
therapy treatment contributed differentially to an increase in prostate cancer deaths in control 
patients”.(4-6)   
A difference in treatment distribution between the cases in the SA and CA of a screening trial 
overall is entirely expected and desirable, since the purpose of screening is to find cancer at a stage 
where curative treatment is still possible.(1) Conversely, because of later detection at an advanced 
stage, hormonal therapy is more commonly used in the CA with a larger fraction of advanced cancers.(1, 
7)  
Such treatment differences only cause bias if men with similar tumors are treated differently 
between arms. For instance, if a man with a low-risk PC would be equally likely to receive active 
surveillance or undergo surgery or radiotherapy, regardless of whether the cancer was detected through 
screening in the SA or through clinical detection in the CA, then a treatment selection bias is an unlikely 
explanation for the mortality differences between groups.  
An earlier study from the ERSPC, comparing the treatment distribution between the trial arms 
by patient and tumor characteristics, showed that a man with non-metastasized high-risk PC in the CA 
was more likely to receive radiotherapy, hormonal treatment or surveillance, compared to a similar man 
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in the SA. However, trial arm had only a minor role in the choice of treatment as compared to clinical 
and pathological variables.(8) Nevertheless, the potential impact of any differential treatment on the PC 
mortality results of the ERSPC trial has not previously been investigated. 
We undertook the present study to estimate the PC mortality that would have been observed in 
the SA, if similar primary treatment had been applied with identical outcomes as in the CA, by clinical 
risk. 
Methods 
The design of the ERSPC has been described previously.(9) The study population of the present analysis 
encompassed all 14,136 men diagnosed with PC (7,310 in the SA; 6,826 in the CA), in the core age group 
55-69 years at randomization (analysis to core age group predefined at the outset(9) and age band that 
is shared by all centers), in four centers: Finland (n=8,046), Netherlands (n=3,700), Sweden (n=1,406), 
and Switzerland (n=984). These four centers were chosen as they are the largest centers that contribute 
the most data to the ERSPC trial, and that all had clinical prognostic and treatment variables available for 
comparability. Cases included those diagnosed from randomization date to December 31, 2013, 
truncated at 16 years of follow-up.   
Surveillance was defined as either active surveillance or watchful waiting. Only primary 
treatment was available for analysis and was categorised as radical prostatectomy, radiotherapy, 
surveillance, or hormonal therapy alone. If hormonal treatment was recorded as primary treatment, 
followed by radical prostatectomy or radiotherapy, then the treatment with curative intent was used. A 
total of 193 cases (108 in the SA; 85 in the CA) with other or unknown primary treatment were excluded 
from the main analysis. Deaths were ascertained by linkage with national registries, and causes of death 
were evaluated in a blinded manner by an independent cause of death committee following a standard 
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algorithm(10), except in Finland where a very high concordance (97%, kappa 0.95) between the 
committee assignments and official causes of death has been established and hence the official cause of 
death were used(11). 
Statistical analysis 
We used a potential outcomes approach applying a counterfactual method, estimating what the 
outcome would have been, if the (counterfactual) treatment allocation in one trial arm had been 
identical to that in the other arm, while the risk of dying from PC remained the same once the choice of 
treatment was fixed(12, 13). In short, this was done in the following steps (see Figure 1): 
I. One model for treatment allocation was fitted for each arm separately. 
II. For each arm and treatment, a model for PC death was fitted.
III. The expected number of men in SA dying from PC had they been allocated a treatment as in CA 
was calculated by combining I and II. The same procedure was carried out for the men in CA. 
IV. The potential outcome in SA, that is the expected number of men in SA dying from PC, had they
been allocated a treatment as in CA, was compared to the observed outcome, and 
correspondingly for CA.
Details of the different steps follow below: 
I. Treatment allocations models 
Treatment allocation was modeled by means of multinomial logistic regression, for the SA and CA 
separately. The following variables were used as covariates: center, age at diagnosis (years), year at 
diagnosis (≥year 2000 vs. <2000; this year was chosen to mark the start of the PSA era and noticeable 
uptick in the incidence of PC detected at a curable stage in Europe (14, 15); a sensitivity analysis was 
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performed split at year 2005, when combined treatment for localized disease became available), PSA 
level (to reflect clinical risk grouping: ≤10 ng/mL; >10 and ≤20; >20; missing or 0), Grade Group (1; 2-3; 
4-5; missing), clinical T stage (T1abc/Tx/missing; T2; T3-4), N and M stage (both N0 and M0; at least one 
N1 or M1; otherwise missing). 
II. PC death models 
For each treatment, logistic regression models were fitted for risk of PC death. This was done separately 
for the screening and control arms. Log of follow-up time from randomization was used as offset(16, 
17).  The same variables were used as covariates as for the treatment allocation models. 
III. Potential outcomes in SA and CA, had the men been given treatments as in the opposite arm
For the men in SA: 
a. The treatment allocation model based on CA was used to estimate potential treatments based 
on the men´s individual values of the covariates.
b. For each treatment, the risk of PC death was estimated for each man based on his values of the 
covariates using the PC death models based on SA (the true arm). 
c. The estimates in a. and b. were combined to achieve the risk of PC death for each man. The risk 
can be seen as a weighted average of the risk of PC deaths for the different treatments (using 
the total probability theorem).
d. Summing these numbers over all men in SA gives the expected number of PC deaths.
The same procedure was carried out for the men in CA. 
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The potential outcome in SA, that is the expected number of men in SA dying from PC, had they been 
allocated a treatment as in CA, was compared to the observed outcome, and correspondingly for CA.  
In order to estimate the uncertainty in the estimates, non-parametric bootstrapping was used; 
2000 bootstrap samples were drawn, and the whole procedure was applied to each bootstrap sample. 
Confidence intervals for the difference in the number and proportion of the different treatments, and in 
PC deaths were then derived by means of the so-called basic method(18). Categories for missing data 
were used in the main analysis. As a sensitivity analysis, modeling was performed on complete cases 
only. Furthermore, three more sensitivity analyses were carried out: cut-off for year of diagnosis at 2005 
instead of 2000; excluding one center at a time; men with “Other/unknown” treatment were given 
treatments in an extreme fashion (all men with missing in one arm got the same treatment and similarly 
for the other arm, for all combination of treatments) (Supplementary Appendix A). 
Simulations of different scenarios were performed in order to show that the modeling strategy 
gave reliable results (Supplementary Appendix B). The actual trial data was used, but treatments and PC 
deaths were altered in a random fashion in two different scenarios. In the first scenario, treatment 
distributions and risks of death were chosen so that there was a theoretical difference between 
“observed” PC deaths in CA and predicted by the treatment model based on SA, and vice versa. In the 
second scenario, a random reordering of PC deaths and treatments were done, which should lead to 
that “observed” and predicted PC deaths were the same. Statistical analyses were performed using R 
version 3.3.1. 
A step-by-step “toy” example of the methodology is illustrated in Supplementary Appendix C. 
IV. Comparison of observed and potential number of PC deaths 
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Results 
The analysis comprised 14,136 men with a follow-up of 16 years. Supplementary Table 1 shows the 
number of PC cases by center and trial arm, with Finland contributing with the largest number of 
participants, followed by the Netherlands, Sweden and Switzerland.   
Screening introduced a stage and grade shift, with a higher proportion of tumors of lower stage 
and grade in the SA compared to the CA and conversely, fewer men with metastasized disease in the SA 
(Table 1).   
Supplementary Table 2 shows the distributions of treatment by trial center and trial arm. 
Surveillance and radical prostatectomy was used more frequently in the SA and, conversely, radiation 
therapy and hormonal therapy were more common in the CA. Surveillance was frequently utilized in 
both trial arms in Sweden (45% in the SA and 34% in the CA) whereas radiotherapy was frequently used 
in both trial arms in Finland and the Netherlands. Radical prostatectomy was common in Switzerland. 
Figure 2 (data included in Table 2) shows the observed and estimated treatment distributions by 
trial arm for the four centers together. Adjusting for center, age at diagnosis, year at diagnosis, PSA-
level, Grade Group, and TNM stage, the difference between the estimated (adjusted) and observed 
treatment distributions in the respective arms was marginal. When comparing the estimated differences 
(after controlling for clinical and pathological variables) with the observed treatment distributions 
between the ERSPC trial arms, the residual discrepancies weremarginal: hormonal therapy [0.1% vs. 
9.4%], radical prostatectomy [0.8% vs. 10.1%], radiotherapy [3.3% vs. 7.9%], and surveillance [2.6% vs. 
7.2%]. 
Similarly, as seen in Table 3, the difference in the estimated and observed number of PC deaths 
was very small. We estimated a reduction in the between-group risk of PC mortality to be 0.01% [95% CI 
-0.2%, 0.2%] when applying the SA model to the CA and 0.05% (95% CI (-0.1%, 0.2%) when applying the 
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CA model SA, had the two groups received identical primary treatment given clinical characteristics. 
Because the observed difference between groups was 4.2%, our findings suggest that differential 
treatment explains only a trivial proportion of the main findings of the ERSPC trial. Similar findings were 
seen in a complete case only analysis (Figure 3, data included in Table 2).  
In our simulation studies of our method, the estimates produced by our approach were similar to 
those entered as parameters in the simulations, hence supporting the reliability of the results presented 
here (Supplementary Appendix B). In the sensitivity analyses the absolute difference between observed 
and estimated PC deaths were less than 0.2%, except for the case where Finland was excluded. Then the 
SA model led to a somewhat lower number of estimated PC deaths in the control arm, and the 
difference was 0.5% (Supplementary Appendix A).  
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Discussion 
We undertook the present study to assess the contribution of treatment differences on the observed PC 
mortality reduction between trial arms in ERSPC.   
Despite slight differences in treatment distributions between trial arms adjusted for prognostic 
variables, these differences in treatment had little effect on PC mortality. The difference in the number 
of PC deaths between the estimated and observed models was small (0.01%-0.05%). Therefore, it is 
unlikely that the reduction in PC mortality in the ERSPC trial is attributable to differential treatment 
between the trial arms, rather, the PC mortality reduction mainly reflects the effect of PSA-screening 
leading to early detection, allowing for effective management. 
The study has several strengths. Rather than using strata of tumor risk groups, prognostic 
variables were included in multivariable models predicting treatment and PC death, respectively. This 
approach minimizes subtle differences in tumor characteristics, which would have been missed if data 
had been categorized into risk groups. In particular the high-risk group, as generally defined, is very 
heterogeneous. For instance, a man with screen-detected small volume, Grade Group 4, clinically non-
palpable tumor (clinical stage T1c) with a low PSA-value, would be classified as “high-risk”, as would a 
man with Grade Group 5, T3 tumor and a high PSA up to 100 ng/mL. Because of this heterogeneity in 
risk grouping, patients in the CA may still have more advanced tumor features compared to men in the 
SA, within similar risk groups.  Using multivariable models rather than risk grouping thus aims to account 
for any slight difference in treatment distribution that can occur within risk groups, even if men with 
similar disease are treated similarly irrespective of trial arm.  
Furthermore, men in the SA were slightly younger at diagnosis (median 67 years) compared to 
corresponding men in the CA (median 69 years), which might affect treatment choice. Even if the age 
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difference is small, it may result in more aggressive treatment for men in the SA. We addressed this by 
adjusting for age.  
As men in the CA were treated later in time, because they were diagnosed more recently 
compared to men in the SA (due to lead-time gained by screening), new, effective treatments could 
have become available for men in the CA. For instance, during the study period, multimodal treatment 
of locally advanced PC has been shown to yield more favourable outcomes than surgery or radiation 
alone.(19) In the Dutch center, a prior study from ERSPC reported that treatment patterns differed 
slightly between the trial arms; for instance, RT was more often combined with hormonal therapy and 
radiation dosages was often higher than 69 Gy in the CA, relative the SA, likely reflecting later detection 
in the CA and development and adoption of novel treatment modalities over time.(20) Despite these 
differences favoring the CA, differences in disease-free survival between the arms were reported to be 
minimal.(20) We attempted to control for the effect of treatment development over the study period by 
adjusting for year of treatment, however lack of granular information regarding treatment received 
remains a limitation of this study.  
Another strength is that the study is based on a very large patient material and the setting of a 
randomized screening trial, which is a major advantage, increasing comparability between the arms. 
Data from each center were sent in to an independent central database every 6 months from the 
beginning of this study. A quality control committee ensured standardized tumor classification within 
each center. A pathology committee co-ordinated biopsy grading. A PSA committee conducted inter-
comparisons of all laboratories involved in the trial. The primary endpoint, i.e. death from PC, was 
evaluated by COD committees who analyzed deaths in men with PC in a blinded fashion i.e. unaware of 
trial allocation.(9, 10)  
The study is not devoid of limitations. The study is limited by only being able to include four 
centres of the ERSPC in the analysis and still having some missing data on prognostic factors (slightly 
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more missing data in the CA) and lack of detailed treatment information, because only primary 
treatment data was collected in the trial. Any effect of secondary treatment upon disease recurrence on 
PC mortality would be smaller compared to primary treatment with curative intent and we have no 
reason to believe that men in the SA received more frequent or higher-quality secondary treatments 
compared to the CA. The current study did not aim to address whether treatment quality differed 
between the trial arms, or whether men received treatment at academic high-volume centers in one 
arm more frequently than in the other. It has been hypothesized that “men in the screening group 
received treatment at a few centers that specialized in treatment of prostate cancer [whereas] the men 
in the control group received standard care in their community [and] that is likely to account for some 
and possibly all of the survival benefit”(3). In the Netherlands’ center, men diagnosed with PC were 
referred back to their primary care physicians for further management and referral. In the Swedish, 
Finnish and Swiss centers, and because the studies were concentrated to defined geographical areas, 
the same referral hospitals were largely responsible for treatments of men in both arms (21, 22). 
Conclusion 
Based on multivariable modeling data from the ERSPC trial, differences in the receipt of primary 
treatment between the SA and CA were minimal and the potential effect of these differences on PC 
mortality was extremely small. These findings suggest that the effectiveness of PSA screening in 
reducing PC mortality in the ERSPC trial was largely due to early detection, allowing for effective 
management, and was not attributable to differential treatment between trial arms. 
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Table 1. Patient characteristics  
Missing includes men with unknown or other treatment 
IQR=Interquartile range, T=tumor, N=node, M=metastasis 
Screening arm Control arm Total 
Number of men 7,310 6,826 14,136 
Age at diagnosis, median (IQR) (years) 67 (64, 71) 69 (66, 73) 68 (65, 72) 
PSA at diagnosis, median (IQR) (ng/mL) 6.0 [4.1, 10.5] 9.8 [6.3, 18.4] 7.7 [4.7, 14.0] 
  Missing, n (%) 159 (2%) 316 (5%) 475 (3%) 
Time from diagnosis to treatment, 
median (IQR), days 
54 (33, 89) 47 (26, 80) 50 (29, 84) 
  Missing, n (%) 330 (5%) 357 (5%) 687 (5%) 
Follow-up from diagnosis, 
median (IQR), years 
7.6 (4.2, 11.6) 5.5 (2.4, 8.8) 6.8 (3.2, 10.6) 
Biopsy Grade Group, n (%) 
  1 4680 (64%) 3,137 (46%) 7,817 (55%) 
  2-3 1671 (23%) 2,185 (32%) 3,856 (27%) 
  4 395 (5%) 574 (8%) 969 (7%) 
  5 339 (5%) 662 (10%) 1,001 (7%) 
  Missing 225 (3%) 268 (4%) 493 (4%) 
Clinical T stage, n (%) 
  T1a,b,c 4,585 (63%) 3,632 (53%) 8,217 (58%) 
  T2 1,818 (25%) 1,609 (24%) 3,427 (24%) 
  T3 708 (10%) 1,169 (17%) 1,877 (13%) 
  T4 128 (2%) 293 (4%) 421 (3%) 
  Missing 71 (1%) 120 (2%) 191 (1%) 
Clinical M stage, n (%) 
  M0 5,164 (71%) 4,371 (65%) 9,535 (68%) 
  M1 259 (4%) 559 (8%) 818 (6%) 
  Missing 1,848 (25%) 1,846 (27%) 3,694 (26%) 
Clinical N stage, n (%) 
  N0 2,942 (40%) 1,614 (24%) 4,556 (32%) 
  N1 85 (1%) 166 (2%) 251 (2%) 
  Missing 4,283 (59%) 5,046 (74%) 9,329 (66%) 
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Table 2. Observed and estimated treatments by trial arm among men with prostate cancer (data illustrated in Figure 2) 
Screening arm (SA) Difference 
(CA – SA) 
Control arm (CA) Difference (SA 
– CA)
Treatment Observed 
N (%) 
Estimated 
CA model 
N (%) 
Difference: 
Estimated 
CA model – 
observed in 
SA  
% (95% CI) 
Observed (%) Observed 
N (%) 
Estimated 
SA model  
N (%) 
Difference: 
Estimated 
SA model 
– observed 
in CA 
% (95% CI) 
Observed (%) 
Hormonal therapy 692 
(9.6%) 
709  
(9.8%) 
 0.2%  
(-0.5, 0.9) 
9.4% 1,274 
(19.0%) 
1,271 
(18.9%) 
-0.1%  
(-1.3, 1.2) 
-9.4% 
Radical Prostatectomy 2,315 
(32.0%) 
2,298 
(31.8%) 
-0.2%  
(-2.0, 1.5) 
-10.1% 1,472 
(21.9%) 
1,523 
(22.7%) 
 0.8%  
(-0.5, 2.1) 
10.1% 
Radiotherapy 2,202 
(30.5%) 
2,441 
(33.8%) 
 3.3%  
(1.6, 5.0) 
7.9% 2,575 
(38.4%) 
2,351 
(35.0%) 
-3.3%  
(-5.0, -1.6) 
-7.9% 
Surveillance 2,016 
(27.9%) 
1,777 
(24.6%) 
-3.3%  
(-4.9, -1.7) 
-7.2% 1,387 
(20.7%) 
1,563 
(23.3%) 
 2.6%  
(1.4, 3.8) 
7.2% 
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Table 3. Observed and estimated numbers of prostate cancer deaths among men with prostate cancer (data illustrated in Figure 3) 
Screening Arm (SA) Difference 
(CA – SA) 
Control Arm (CA) Difference (SA – CA) 
Observed 
N (%) 
Estimated 
CA model  
N (%) 
Difference: 
Estimated CA 
model – 
observed in SA 
% (95% CI) 
Observed 
(%) 
Observed 
N (%) 
Estimated 
SA model  
N (%) 
Difference: 
Estimated SA 
model – 
observed in CA 
% (95% CI) 
Observed (%) 
Main analysis:  
All data 
442 
(6.1%) 
446.6 
(6.2%) 
0.05%  
(-0.1%, 0.2%) 
4.2% 691 
(10.3%) 
691.8 
(10.3%) 
0.01%  
(-0.3%, 0.2%) 
-4.2% 
Sensitivity analysis: 
Complete cases 
388 
(5.7%) 
390.4 
(5.7%) 
0.03%  
(-0.2%, 0.2%) 
3.8% 580 
(9.5%) 
580.8 
(9.5%) 
0.01%  
(-0.3%, 0.3%) 
-3.8% 
Tumor nodal (N)- and metastasis (M)- stages are not used for death models in the sensitivity analysis 
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Supplementary Table 1. Number of men by trial center and trial arm 
Number of men with prostate cancer* 
Number of men randomized  
(without prostate cancer at the time of 
randomization) 
Center Screening arm 
N (%) 
Control arm 
N (%) 
Total 
N (%) 
Screening arm 
N (%) 
Control arm 
N (%) 
Total 
N (%) 
Finland 3,500 (48%) 4,546 (67%) 8,046 (57%) 31874 (53%) 48302 (63%) 80176 (59%) 
Netherlands 2,376 (33%) 1,324 (19%) 3,700 (26%) 17422 (29%) 17379 (23%) 34801 (26%) 
Sweden 814 (11%) 592 (9%) 1,406 (10%) 5901 (10%) 5950 (8%) 11851 (9%) 
Switzerland 620 (9%) 364 (5%) 984 (7%) 4920 (8%) 4929 (6%) 9849 (7%) 
Total 7,310 (100%) 6,826 (100%) 14,136 (100%) 60117 (100%) 76560 (100%) 136677 (100%) 
*Includes men with unknown or other treatment
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Supplementary Table 2. Primary treatment by trial center and trial arm 
Center Hormonal Therapy Radical 
Prostatectomy 
Radiotherapy Surveillance Other / 
Unknown 
Total 
SA CA SA CA SA CA SA CA SA CA SA CA 
Finland 493 
(14%) 
898 
(20%) 
951 
(27%) 
910 
(20%) 
1,230 
(35%) 
1,855 
(41%) 
775 
(22%) 
787 
(17%) 
51  
(2%) 
96 
(2%) 
3,500 
(100%) 
4,546 
(100%) 
Netherlands 90  
(4%) 
184 
(14%) 
774 
(33%) 
229 
(17%) 
833 
(35%) 
598 
(45%) 
667 
(28%) 
308 
(23%) 
12  
(0.5%) 
5 
(0.4%) 
2,376 
(100%) 
1,324 
(100%) 
Sweden 98  
(12%) 
167 
(28%) 
271 
(33%) 
150 
(25%) 
72  
(9%) 
60 
(10%) 
364 
(45%) 
200 
(34%) 
9  
(1%) 
15 
(3%) 
814 
(100%) 
592 
(100%) 
Switzerland 11  
(2%) 
25 (7%) 319 
(52%) 
183 
(50%) 
67 
(11%) 
62 
(17%) 
210 
(34%) 
92 
(25%) 
13  
(2%) 
2 
(0.5%) 
620 
(100%) 
364 
(100%) 
Total 692 
(10%) 
1,274 
(19%) 
2,315 
(32%) 
1,472 
(22%) 
2,202 
(30%) 
2,575 
(38%) 
2,016 
(28%) 
1387 
(20%) 
85  
(1%) 
118 
(2%) 
7,310 
(100%) 
6,826 
(100%) 
SA=screening arm, CA=control arm 
Includes men with unknown or other treatment 
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Figure 1. Description of study methodology 
Abbreviations: SA=screening arm; CA=control arm, dg=diagnosis, TNM=tumor, nodes, metastasis stage, PSA=prostate specific antigen, 
Tx=treatment; PC=prostate cancer  
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Figure 2. Observed and estimated treatments by trial arm (data included in Table 2) 
SA=Screening Arm, CA=Control Arm, N=Number, CI=Confidence Interval, obs=observed, est=estimated, HT=Hormone Therapy, RP=Radical 
Prostatectomy, RT=Radiotherapy, S=Surveillance 
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Figure 3. Observed and estimated numbers of prostate cancer deaths (data included in Table 3) 
SA=Screening Arm, CA=Control Arm, N=Number, CI=Confidence Interval, obs=observed, est=estimated, HT=Hormone Therapy, RP=Radical 
Prostatectomy, RT=Radiotherapy, S=Surveillance 
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Supplementary Appendix A. Sensitivity analyses 
One center at a time excluded 
Excluded 
center 
Obs SA Est 
CA model, SA 
Diff 
Est_Obs_SA 
Obs CA Est 
SA model, CA 
Diff 
Est_Obs_CA 
Finland 192 (5.1%) 197.5 (5.2%) 5.5 (0.2%) 277 (12.3%) 265.4 (11.8%) -11.6 (-0.5%) 
Netherlands 324 (6.7%) 329.4 (6.8%) 5.4 (0.1%) 516 (9.6%) 520 (9.7%) 4 (0.07%) 
Sweden 389 (6.1%) 392.4 (6.1%) 3.4 (0.05%) 613 (10%) 613.1 (10%) 0.1 (0%) 
Switzerland 421 (6.4%) 425.2 (6.4%) 4.2 (0.06%) 667 (10.5%) 668 (10.5%) 1 (0.02%) 
Cut-off for year of diagnosis 
CutOff 
year 
Obs SA Est 
CA model, SA 
Diff 
Est_Obs_SA 
Obs CA Est 
SA model, CA 
Diff 
Est_Obs_CA 
2005 442 (6.1%) 447.9 (6.2%) 5.9 (0.08%) 691 (10.3%) 688.8 (10.3%) -2.2 (-0.03%) 
An additional PSA category (0-5 ng/ml) 
Obs SA Est 
CA model, SA 
Diff 
Est_Obs_SA 
Obs CA Est 
SAmodel, CA 
Diff 
Est_Obs_CA 
442 (6.12%) 446.5 (6.2%) 4.5 (0.06%) 691 (10.3%) 692 (10.3%) 1 (0.01%) 
Unknown / Other treatment replaced and all men included in analysis 
SA 
Replacement 
for 
other/unknown 
treatment 
CA 
Replacement 
for 
other/unknown 
treatment 
Obs SA Est 
CAmodel, 
SA 
Diff 
Est_Obs_SA 
Obs CA Est 
SAmodel, 
CA 
Diff 
Est_Obs_CA 
Hormonal 
Therapy 
Hormonal 
Therapy 
448 
(6.1%) 
452.3 
(6.2%) 
4.3 (0.06%) 712 
(10.4%) 
718.4 
(10.5%) 
6.4 (0.09%) 
Hormonal 
Therapy 
Radical 
Prostatectomy 
448 
(6.1%) 
446.7 
(6.1%) 
-1.3 (-0.02%) 712 
(10.4%) 
725.5 
(10.6%) 
13.5 (0.2%) 
Hormonal 
Therapy 
Radiotherapy 448 
(6.1%) 
446.5 
(6.1%) 
-1.5 (-0.02%) 712 
(10.4%) 
722.3 
(10.6%) 
10.3 (0.2%) 
Hormonal 
Therapy 
Surveillance 448 
(6.1%) 
446.4 
(6.1%) 
-1.6 (-0.02%) 712 
(10.4%) 
723.7 
(10.6%) 
11.7 (0.2%) 
Radical 
Prostatectomy 
Hormonal 
Therapy 
448 
(6.1%) 
455.6 
(6.2%) 
7.6 (0.1%) 712 
(10.4%) 
699.4 
(10.3%) 
-12.6 (-0.2%) 
Radical 
Prostatectomy 
Radical 
Prostatectomy 
448 
(6.1%) 
451.3 
(6.2%) 
3.3 (0.05%) 712 
(10.4%) 
712.7 
(10.4%) 
0.7 (0.01%) 
Radical 
Prostatectomy 
Radiotherapy 448 
(6.1%) 
448.4 
(6.1%) 
0.4 (0%) 712 
(10.4%) 
704.5 
(10.3%) 
-7.5 (-0.1%) 
Radical 
Prostatectomy 
Surveillance 448 
(6.1%) 
448.3 
(6.1%) 
0.3 (0%) 712 
(10.4%) 
705.7 
(10.3%) 
-6.3 (-0.09%) 
Radiotherapy Hormonal 
Therapy 
448 
(6.1%) 
458.4 
(6.3%) 
10.4 (0.14%) 712 
(10.4%) 
704.5 
(10.3%) 
-7.5 (-0.1%) 
Radiotherapy Radical 
Prostatectomy 
448 
(6.1%) 
451.1 
(6.2%) 
3.1 (0.04%) 712 
(10.4%) 
712.5 
(10.4%) 
0.5 (0.01%) 
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Radiotherapy Radiotherapy 448 
(6.1%) 
453.7 
(6.2%) 
5.7 (0.08%) 712 
(10.4%) 
712 
(10.4%) 
0 (0%) 
Radiotherapy Surveillance 448 
(6.1%) 
451 
(6.2%) 
3 (0.04%) 712 
(10.4%) 
710.9 
(10.4%) 
-1.1 (-0.02%) 
Surveillance Hormonal 
Therapy 
448 
(6.1%) 
456.6 
(6.3%) 
8.6 (0.12%) 712 
(10.4%) 
702.8 
(10.3%) 
-9.2 (-0.1%) 
Surveillance Radical 
Prostatectomy 
448 
(6.1%) 
449.7 
(6.2%) 
1.7 (0.02%) 712 
(10.4%) 
711 
(10.4%) 
-1 (-0.01%) 
Surveillance Radiotherapy 448 
(6.1%) 
449.5 
(6.2%) 
1.5 (0.02%) 712 
(10.4%) 
708 
(10.4%) 
-4 (-0.06%) 
Surveillance Surveillance 448 
(6.1%) 
453.5 
(6.2%) 
5.5 (0.08%) 712 
(10.4%) 
713.5 
(10.5%) 
1.5 (0.02%) 
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Supplementary Appendix B. Validation of modelling procedure by simulations 
Does modelling procedure give unbiased results regarding number of prostate cancer (PC) deaths 
between observed and modelled in case: 
1. There is a true difference between observed and expected
2. There is no true difference between observed and expected
In both cases the covariate values were kept for each individual. The same scripts as for the results in 
the manuscript are used.  
There is a true difference 
In this part treatments and risk of death are chosen so that there is a theoretical difference between 
"observed" and what is expected by the treatment model based on the other group. This is done by 
assuming that there is a higher risk of death if hormonal treatment is given, and that the chance of 
getting hormonal treatment is different in the two arms. 
Assumptions (“truth”): 
 Control arm (CA): 
 Treatments: p = 1/4 for all treatments 
 PC death: All treatments except hormonal: p = 1/10; Hormonal treatment: p = ½ 
 Truth: 
 Exp[# of deaths] = 1341.6
 Exp[# of deaths w treatments as in SA] = 2012.4
 ∆ = 670.8 
 Screening arm (SA): 
 Treatments: All treatments except hormonal: p = 1/6; Hormonal treatment: p = ½ 
 PC death:  Same as for CA 
 Truth: 
 Exp[# of deaths] = 2167.5
 Exp[# of deaths w treatments as in CA] = 1445.0 
  ∆ = -722.5 
Modelling (1000 simulations): 
 Control arm: Mean difference in PC deaths with SA treatment model and “truth" in CA: 671.3
 Screening arm: Mean difference in PC deaths with CA treatment model and “truth" in SA: -722.7 
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There is no true difference 
This is illustrated by means assuming that PC deaths are distributed at random between men (the same 
number as in the original data) 
Assumptions (“truth”): 
 Control arm (CA): 
o Treatments: Kept as in original data 
o PC deaths: Distributed at random between men (the same number as in the original 
data) whichever treatment  treatment distribution does not matter 
 Truth: 
 Exp[# of deaths] = Observed = 691
 Exp[# of deaths w treatments as in SA] = 691
 ∆ = 0 
 Screening arm (SA): As for CA 
 Truth: 
 Exp[# of deaths] = Observed = 442
 Exp[# of deaths w treatments as in CA] = 442 
 ∆ = 0 
Modelling (1000 simulations): 
 Control arm: Mean difference in PC deaths with SA treatment model and “truth" in CA: 0.4
 Screening arm: Mean difference in PC deaths with CA treatment model and “truth" in SA: 2
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Supplementary Appendix C. “Toy” example to illustrate the methodology 
We want to compare observed number of PC deaths in the CA with the expected if the men had 
received treatments as in the SA, given their clinical characteristics. For simplicity we assume  
 In each of the SA and the CA, 100 men were diagnosed with PC 
 The only covariate we consider is age at diagnosis, which is divided into <70 and ≥ 70 years
 Only two treatments are available: hormonal (H) and surgery (S) 
The number of men in the different age categories, on the different treatments, and whether they died 
from PC or not, were distributed as follows in the two arms: 
Since there is only one covariate (age at diagnosis) with only two levels, the modelling can be seen 
simply as calculating a number of proportions. Below, the notation P(A) should be read as “the 
probability of A)”. 
To be able to calculate the expected number of deaths in CA if they had received treatments as in SA, 
we need a treatment model based on SA and a death model based on CA: 
I. A model for treatment allocation was fitted for the SA with age as covariate: 
 If age < 70 then P(hormonal) = 12/60 and P(surgery) = 48/60
 If age ≥ 70 then P(hormonal) = 20/40 and P(surgery) = 20/40
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II. For each treatment, a model for PC death was fitted for the CA with age as covariate: 
 Hormonal treatment:
 If age < 70 then P(PC death) = 2/10
 If age ≥ 70 then P(PC death) = 5/35
 Surgery:
 If age < 70 then P(PC death) = 0
 If age ≥ 70 then P(PC death) = 3/25
The expected number of men in CA dying from PC had they been allocated a treatment as in SA is 
calculated by combining the treatment model based on SA (from I) and the PC death model based on CA 
(from II): 
III. The probability of PC death for each man in CA is a weighted average of the risk of PC deaths for 
the different treatments: 
 If age < 70 years: 
P(PC death) = P(PC death if trt=H) * P(trt = H) + P(PC death if trt=S) * P(trt = S) = 2/10 * 
12/60 + 0 * 48/60 =   0.04
 If age ≥ 70 years: 
P(PC death) = P(PC death if trt=H) * P(trt = H) + P(PC death if trt=S) * P(trt = S) = 5/35 * 
20/40 + 3/25 * 20/40 =   0.13
Summing over the 100 men in CA, 40 of which were less than 70 years at diagnosis, leads to 
40*0.04 + 60*0.13= 9.5 expected deaths. 
IV. This number is then compared to the observed number of PC deaths in CA which was 10 deaths.
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